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therapeutic choice because the mortality is
lower than that of surgical treatment and
its application is easy and rapid.1,2
We do not know with certainty how long
it takes thrombolytic therapy to deocclude
a thrombosed prosthesis, although it proba-
bly takes less time than surgery because of
all the equipment needed to implement
aggressive treatment.
The great risk of a redo valve replace-
ment in these generally critically ill patients
is also widely appreciated. The main risks of
thrombolytic treatment are the thromboem-
bolic complications, which appear in from
4% to 13% of the patients, and bleeding,
which occurs in from 1.4% to 5%.3
We have read with interest the excellent
report written by Nguyen and collegues.4
They have added an important case to the
medical literature for the successful applica-
tion of the thrombolytic protocol with
recombinant tissue-type plasminogen acti-
vator (rt-PA), which has not been used
previously in the management of PVT. It
consisted in a continuous intravenous infu-
sion of rt-PA at a rate of 1 mg/h together
with the administration of heparin in a con-
tinuous intravenous infusion of 3 U $ kg21 $
h21. The duration of treatment was 80
hours. At the end of the fibrinolytic infusion,
the transprosthetic gradients had decreased
from a peak and mean of 158 and 86 mm
Hg to 48 and 25 mm Hg, respectively. Fluo-
roscopy confirmed normal motion of the
prosthetic valve. The patient’s symptoms re-
solved.
We would like to make some comments
related to this therapeutic regimen. Treat-
ment with rt-PA in PVT has not been widely
used. It has been blamed for a major risk of
embolism other than thrombolysis for its po-
tential and velocity of the infusion. Shapira
and collegues5 proved the efficacy and
safety of rt-PA, with the additional advan-
tage that if the thrombolytic treatment fails,
surgery can be used with less risk for its less
lytic systemic effect.
The regimen of administration is not
well defined. This protocol probably needs
a longer course and lower dose to provide
better thrombolytic efficacy with less risk
of complications in hemodynamically stable
patients, because they do not need a prompt
thrombolytic effect. An accelerated protocol
with rt-PA should be reserved for critically
ill patients.
Until now, streptokinase is the most ef-
fective thrombolytic agent used, alone or
as a part of a sequential fibrinolytic treat-
ment in the PVT.
Despite the favorable evidence of throm-
bolytic therapy in the treatment of the PVT,
more data should be gathered to obtain
a general consensus of the ideal manage-
ment of this complication.
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Letters to the EditorOptimizing selective cerebral
perfusion in adult aortic arch
repair: Clinical relevance of the
laboratory model
To the Editor:
I read with great interest the excellent article
by Halstead and colleagues1 detailing in
their porcine model of deep hypothermic
circulatory arrest (DHCA) the neuroprotec-
tive effects of selective cerebral perfusion
(SCP) via both carotid arteries at a mean
of 50 mm Hg for a period of 90 minutes.
In this laboratory model, the authors have
clearly demonstrated the adverse cerebral
effects associated with SCP at higher pres-The Journal of Thoracic and Cardiovasculsures and flow rates. The clinical relevance
of this observation is illustrated in the study
by Khaladji and colleagues,2 in which they
analyze outcomes after hypothermic circu-
latory arrest (71.1% hemiarch; 10.4% total
arch) and bilateral cold selective SCP at
a perfusion pressure of 40 to 60 mm Hg
with flow rates of 400 to 650 mL/min.
However, Halstead and colleagues chose
a long SCP time of 90 minutes, which is the
time required for a total arch repair. In an ear-
lier clinical study, these investigators3 dem-
onstrated their technique with a trifurcated
graft with mean DHCA/SCP times of 31.1
6 6.6 minutes and 65.36 20.9 minutes, re-
spectively, with SCP perfusion pressures of
50 to 70 mm Hg with flow rates of 800 to
1200 mL/min. Hence, this latest laboratory
study is part of their ongoing quest to opti-
mize their technique of total arch replace-
ment with SCP, and it suggests a new
range for bilateral SCP perfusion pressures
and flow rate.
However, although this model is clini-
cally relevant for hemiarch repairs,2 how
might it apply in the case of aortic arch repair
with unilateral SCP?4Would lower SCP per-
fusion pressures be clinically superior, as-
suming a clinically competent circle of
Willis? Or would the contralateral brain be
at significant risk of ischemia, given the rel-
evant incidence of clinical inadequacy in the
circle of Willis for cerebral perfusion in
DHCAwith unilateral SCP?5 Do the authors
plan to evaluate unilateral SCP in their por-
cine DHCA model?
I congratulate the authors again on their
important contribution. I look forward to their
comments about these aspects of selective ce-
rebral perfusionduring adult aortic arch repair.
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